Disclosed are oligonucleoside boranophosphates, or salts thereof, comprising a chain of natural or modified ribonucleotides or deoxyribonucleotides, containing at least one boronated internucleotide phospodiester linkage of the formula: ##STR1## W is selected from the group consi

A process of making oligoribonucleoside and deoxyribonucleoside boranophosphates and salts thereof is disclosed. The process comprises the steps of condensing a ribonucleotide or deoxyribonucleotide with a nucleoside phosphitylating agent, wherein the phosphitylating agent includes a

A novel class of pharmaceutically active boronated nucleosides are provided. The nucleosides are boronated at a ring nitrogen of the purine or pyrimidine or analogues thereof. Also provided are phosphate esters of these nucleosides and oligomers thereof. Methods of making and using the

A method of controlling hyperlipidemia in mammals which comprises adminstering to a mammal an amount effective to control hyperlipidemia of a compound having hypolipidemic activity and the structural formula: ##STR1## wherein R.sup.1 and R.sup.2, which may be the same or different pr

Novel boron dipeptide analogs and their corresponding amide derivatives which exhibit significant antihyperlipidemic and antineoplastic activities. Methods for preparing the boron containing compounds are disclosed as well as methods for utilizing the compounds to induce antihyperlip

An isoxazolidin-3,5-dione for the control of hyperlipidemia in mammals having the following structural formula: ##STR1## wherein R.sup.1 and R.sup.2 are each an alkyl of 1 to 4 carbons; R.sup.3 is an alkoxybenzoyl group containing from 1 to 3 alkoxy groups wherein the alkoxy grou

The present invention is directed to a method of controlling hyperlipidemia in mammals which comprises administering to a mammal an amount effective to control hyperlipidemia of a compound having hypolipidemic activity and the structural formula: ##STR1## wherein R.sup.1 is hydro

A compound having the structural formula ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and are hydrogen, C.sub.1 -C.sub.6 alkyl, halogen or C.sub.1 -C.sub.4 alkoxy is disclosed. These compounds demonstrate utility as hypolipidemic agents.The present invention is also

A compound having the structural formula ##STR1## wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 carbalkoxyalkyl or phenyl substituted with C.sub.1 -C.sub.3 alkyl or halogen; R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl; and R.sup.3 and R.sup.4 are the sam

Long chain alkyl amines are useful as anti-hyperlipidemic agents for lowering serum cholesterol and triglyceride levels in mammals. Such amines include compounds of the formula ##STR1## in which R.sub.1 is alkyl of 8 to 20 carbon atoms and each R.sub.2 is hydrogen or alkyl of 1 t

A process for controlling hyperlipidemia in mammals is disclosed. In this process a mammal suffering from hyperlipidemia is treated with a hyperlipidemia controlling effective amount of a compound having the structural formula ##STR1## wherein R.sup.1 is mercapto, amino, hydroxy

A process for controlling hyperlipidemia in mammals is disclosed. In this process a hyperlipidemia controlling effective amount of a compound having structural formula: ##STR1## where R.sup.1 is hydrogen, oxo, C.sub.1 -C.sub.6 alkyl or C.sub.2 -C.sub.6 alkanoyl; R.sup.2 is hydrog

Ammonium salts of polyboranes are useful as antihyperlipidemic agents for lowering serum cholesterol and triglyceride levels in mammals. Such polyborane ions include the B.sub.3 H.sub.8.sup.- and B.sub.n H.sub.n.sup.= groups in which n is 6 to 12.

Ester analogues of boron analogues of amino acid are disclosed. Also disced is a method of forming the ester analogues in high yield by condensation of the corresponding acids and alcohols with dicylohexylcarbodiimide at room temperature in dichloromethane. The disclosed compounds h

This invention involves amine-carbamoylborane compounds of the formulawherein R.sub.1 and R.sub.2 are hydrogen or certain alkyl moieties and R..3 is an alkyl. A process for their preparation involving an amine displacement reaction is also described. A method of use and pharmaceutical c

A compound of the formulawherein each R independently represents H, C.sub.1 -C.sub.10 alkyl, or phenyl and L represents a non-toxic Lewis base capable of forming a coordinate bond with the copper with the provisos that any two or three R attached to the same nitrogen may represent a C.su

This invention relates to novel N-benzoylsulfamates, N-benzylsulfamates and benzylsulfonamides and pharmacologically acceptable salts thereof, a method for lowering serum levels in mammals by administration of said compounds, and pharmaceutical compositions thereof.

The use of a mine boranes to inhibit the inflammation process is disclosed. hese boranes, which are boron analogs of .alpha.-amino acids, effectively block the following: general inflammation, induced arthritis, and the writhing reflex associated with inflammation pain. The inflammation

The use of amine boranes to inhibit the inflammation process is disclosed. These boranes, which are boron analogs of .alpha.-amino acids, effectively block the following: general inflammation, induced arthritis, and the writhing reflex associated with inflammation pain. The inflammation

Preparation of the crystalline complex [Na{NH.sub.3.BH.sub.2 -(CN)}.sub.6 from NMe.sub.3.BH.sub.2 I and NaCN in liquid NH.sub.3 is disclosed. Structural details of this novel octahedral complex are obtained by single-crystal X-ray analysis. Evidence indicates that the complex is a v